Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phathom Pharmaceuticals Inc PHAT

Healthcare
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are... see more

Recent & Breaking News (NDAQ:PHAT)

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire November 7, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

GlobeNewswire October 28, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

GlobeNewswire October 27, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

PR Newswire September 25, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire August 29, 2024

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire August 19, 2024

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 8, 2024

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

GlobeNewswire July 30, 2024

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

GlobeNewswire July 29, 2024

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

GlobeNewswire July 18, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire May 28, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

GlobeNewswire May 15, 2024

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

GlobeNewswire April 29, 2024

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"

GlobeNewswire March 26, 2024

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 7, 2024

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

GlobeNewswire February 29, 2024

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

GlobeNewswire February 13, 2024